Phase 3 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of signing the consent form
- People who are willing and able to follow all study procedures and are likely to complete the study, based on the doctor's assessment
- People who have been diagnosed with diabetic macular oedema (a diabetes-related swelling in the central part of the eye) affecting the eye being studied
- People whose vision in the study eye falls within a specific range — roughly between 20/40 and 20/200 on a standard eye chart — measured at the screening visit and again on the first day of the study
- People whose vision loss is determined by the study doctor to be mainly caused by the diabetic macular oedema in the study eye
Who may not be able to join:
- People who have previously received anti-VEGF therapy (a type of injection treatment commonly used for certain eye conditions) (confirm with trial site)
- People who have another eye condition, either in the past or currently, that could also affect their vision separately from the diabetic macular oedema
- People who have any condition that, in the study doctor's opinion, could interfere with full participation in the study, pose a significant safety risk, or affect the study results
- People who the study doctor considers unsuitable for any reason, including certain medical or mental health conditions, or concerns that the person may not be able to follow study procedures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +41 78 659 89 89
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from baseline to Week 8 in BCVA as measured by ETDRS letter score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.